Glycogen synthase kinase-3Β regulates astrocytic differentiation of U87-MG human glioblastoma cells

Acta Pharmacologica Sinica

Volumn 31, Issue 3, 2010, Pages 355-360

  Li, Yan ^a,b   Lu, Hui Min ^b   Li, Gang ^a   Yan, Guang Mei ^b  

^a SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

Astrocytes; Differentiation; Glial fibrillary acidic protein; Glioblastoma; Glycogen synthase kinase 3

Indexed keywords

BROXURIDINE; CHOLERA TOXIN; CYCLINE; GLIAL FIBRILLARY ACIDIC PROTEIN; GLYCOGEN SYNTHASE KINASE 3BETA;

ARTICLE; ASTROCYTE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL STRUCTURE; CONTROLLED STUDY; ENZYME REGULATION; GLIOBLASTOMA; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; PHENOTYPE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; TUMOR CELL; WESTERN BLOTTING;

ASTROCYTES; CELL DIFFERENTIATION; CELL LINE, TUMOR; CHOLERA TOXIN; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; GLYCOGEN SYNTHASE KINASE 3; HUMANS;

EID: 77749251930     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2010.10     Document Type: Article

References (27)

1. DeAngelis LM. Brain tumors. N Engl J Med 2001; 344: 114-23.
2. Maher EA, Furnari FB, Bachoo RM, Rowitch DH, Louis DN, Cavenee WK, et al. Malignant glioma: genetics and biology of a grave matter. Genes Dev 2001; 15: 1311-33.
3. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-96.
4. Huang ME, Ye YC, Chen SR, Chai JR, Lu JX, Zhoa L, et al. Use of alltrans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988; 72: 567-72.
5. Leszczyniecka M, Roberts T, Dent P, Grant S, Fisher PB. Differentiation therapy of human cancer: basic science and clinical applications. Pharmacol Ther 2001; 90: 105-56.
6. Li Y, Yin W, Wang X, Zhu W, Huang Y, Yan G. Cholera toxin induces malignant glioma cell differentiation via the PKA/CREB pathway. Proc Natl Acad Sci USA 2007; 104: 13438-43.
7. Ougolkov AV, Billadeau DD. Targeting GSK-3: a promising approach for cancer therapy? Future Oncol 2006; 2: 91-100.
8. Woodgett JR. cDNA cloning and properties of glycogen synthase kinase-3. Methods Enzymol 1991; 200: 564-77.
9. Jope RS, Johnson GV. The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci 2004; 29: 95-102.
10. Kang T, Wei Y, Honaker Y, Yamaguchi H, Appella E, Hung MC, et al. GSK-3 beta targets Cdc25A for ubiquitin-mediated proteolysis, and GSK-3 beta inactivation correlates with Cdc25A overproduction in human cancers. Cancer Cell 2008; 13: 36-47.
11. Ding Q, Xia W, Liu JC, Yang JY, Lee DF, Xia J, et al. Erk associates with and primes GSK-3beta for its inactivation resulting in upregulation of beta-catenin. Mol Cell 2005; 19: 159-70.
12. Wang Y, Lam JB, Lam KS, Liu J, Lam MC, Hoo RL, et al. Adiponectin modulates the glycogen synthase kinase-3beta/beta-catenin signaling pathway and attenuates mammary tumorigenesis of MDA-MB-231 cells in nude mice. Cancer Res 2006; 66: 11462-70.
13. Roymans D, Vissenberg K, De Jonghe C, Grobben B, Claes P, Verbelen JP, et al. Phosphatidylinositol 3-kinase activity is required for the expression of glial fbrillary acidic protein upon cAMP-dependent induction of differentiation in rat C6 glioma. J Neurochem 2001; 76: 610-8.
14. Krishna TS, Kong XP, Gary S, Burgers PM, Kuriyan J. Crystal structure of the eukaryotic DNA polymerase processivity factor PCNA. Cell 1994; 79: 1233-43.
15. Scott RE. Differentiation, differentiation/gene therapy and cancer. Pharmacol Ther 1997; 73: 51-65.
16. Sell S. Stem cell origin of cancer and differentiation therapy. Crit Rev Oncol Hematol 2004; 51: 1-28.
17. Takanaga H, Yoshitake T, Hara S, Yamasaki C, Kunimoto M. cAMP-induced astrocytic differentiation of C6 glioma cells is mediated by autocrine interleukin-6. J Biol Chem 2004; 279: 15441-7.
18. Doble BW, Woodgett JR. GSK-3: tricks of the trade for a multi-tasking kinase. J Cell Sci 2003; 116: 1175-86.
19. Manoukian AS, Woodgett JR. Role of glycogen synthase kinase-3 in cancer: regulation by Wnts and other signaling pathways. Adv Cancer Res 2002; 84: 203-29.
20. Polakis P. The oncogenic activation of beta-catenin. Curr Opin Genet Dev 1999; 9: 15-21.
21. Liao X, Zhang L, Thrasher JB, Du J, Li B. Glycogen synthase kinase-3beta suppression eliminates tumor necrosis factor-related apoptosis-inducing ligand resistance in prostate cancer. Mol Cancer Ther 2003; 2: 1215-22.
22. Mazor M, Kawano Y, Zhu H, Waxman J, Kypta RM. Inhibition of glycogen synthase kinase-3 represses and rogen receptor activity and prostate cancer cell growth. Oncogene 2004; 23: 7882-92.
23. Hoefich KP, Luo J, Rubie EA, Tsao MS, Jin O, Woodgett JR. Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. Nature 2000; 406: 86-90.
24. Schwabe RF, Brenner DA. Role of glycogen synthase kinase-3 in TNF-alpha-induced NF-kappaB activation and apoptosis in hepatocytes. Am J Physiol Gastrointest Liver Physiol 2002; 283: G204-11.
25. la Sala A, He J, Laricchia-Robbio L, Gorini S, Iwasaki A, Braun M, et al. Cholera toxin inhibits IL-12 production and CD8alpha+ dendritic cell differentiation by cAMP-mediated inhibition of IRF8 function. J Exp Med 2009; 206: 1227-35.
26. Kimura M, Hidari KI, Suzuki T, Miyamoto D, Suzuki Y. Engagement of endogenous ganglioside GM1a induces tyrosine phosphorylation involved in neuron-like differentiation of PC12 cells. Glycobiology 2001; 11: 335-43.
27. Masco D, Van de Walle M, Spiegel S. Interaction of ganglioside GM1 with the B subunit of cholera toxin modulates growth and differentiation of neuroblastoma N18 cells. J Neurosci 1991; 11: 2443-52.